Welcome to our dedicated page for TWINLAB CONSOLIDATED HOLDINGS SEC filings (Ticker: TLCC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on TWINLAB CONSOLIDATED HOLDINGS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into TWINLAB CONSOLIDATED HOLDINGS's regulatory disclosures and financial reporting.
TWINLAB CONSOLIDATED HOLDINGS, INC. (TLCC) reports that its key operating subsidiaries—Twinlab Consolidation Corporation, Twinlab Holdings, Inc. and Organic Holdings, LLC—executed assignments for the benefit of creditors on August 21, 2026 under Florida law, transferring substantially all of their non‑exempt assets to an assignee for liquidation and creditor distributions.
The subsidiaries held Twinlab’s branded nutritional supplement operations and contract manufacturing; TLCC itself did not enter an assignment but expects to deconsolidate these entities and record a full impairment of its equity interests, goodwill and related intangibles. Scheduled liquidation value of assigned assets is about $4.0 million versus a $67.5 million secured claim and more than $80.8 million of unsecured claims at TCC, so TLCC does not expect any distribution to subsidiary equity holders or any recovery for holders of TLCC common stock.
An Asset Purchase Agreement dated September 1, 2026 provides for the assignee to sell specified assets (including IP and equity interests in the Assignors) to a cbdMD, Inc. subsidiary for a purchase price of $3,979,805, payable entirely to secured creditor Akretive Holdings, LLC (note assumption plus cbdMD stock). Upon closing, Akretive would waive subsidiary indebtedness but not obligations or liens against TLCC. Closing requires Florida court approval and is subject to higher and better offers; cbdMD would serve as stalking horse with bid protections. TLCC now has no operating business, minimal assets, no meaningful liquidity beyond potential transition‑services fees, is delinquent in Exchange Act reports and may be, or may become, a shell company, raising substantial doubt about its ability to continue as a going concern.
Twinlab Consolidated Holdings, Inc. is a Nevada-based marketer and distributor of branded nutritional supplements and herbal teas, selling primarily through U.S. health and natural food retailers, mass merchants, e‑commerce and international distributors. Key brands include Twinlab®, Reserveage™, ResVitale®, Metabolife® and Alvita®.
The company now operates with a very small team of about 7 full‑time employees and relies entirely on third‑party manufacturers and logistics partners. Its three largest customers accounted for approximately 53% of 2024 sales and 62% of year‑end receivables, creating significant customer concentration risk.
Twinlab discloses a substantial debt load, multiple loan and lease defaults and negative working capital, and warns that these conditions raise substantial doubt about its ability to continue as a going concern. Management states it may need additional capital within 12 months and notes that failure to refinance or settle obligations could force a Chapter 11 bankruptcy filing or allow creditors to pursue involuntary proceedings. The company is also defending a Florida lease-related lawsuit seeking roughly $963,000 in damages, and highlights extensive regulatory, competitive, cybersecurity, operational and penny‑stock trading risks that could further pressure liquidity and equity value.